Literature DB >> 32583381

Health-Related Quality of Life in Sarcoidosis.

Ogugua Ndili Obi1.   

Abstract

Health-related quality of life (HRQoL) describes an individual's perception of the impact of health, disease, and treatment on their quality of life (QoL). It is a reflection of how the manifestation of an illness and its treatment is personally experienced. Assessing HRQoL is particularly important in sarcoidosis because the attributable disease mortality is relatively low, and one of the major reasons for initiating treatment is to improve quality of life. HRQoL has been assessed in sarcoidosis using various generic and sarcoid-specific patient-reported outcome measures (PROMs). It is important that both the direct and indirect effects of the disease, as well as potential toxicities of therapy, are captured in the various PROMs used to assess HRQoL in sarcoidosis. This article provides a general overview of HRQoL in patients with sarcoidosis. It describes the various PROMs used to assess HRQoL in sarcoidosis and addresses the various factors that influence HRQoL in sarcoidosis. Specific attention is paid to fatigue, small fiber neuropathy, corticosteroid therapy, and other disease-specific factors that affect HRQoL in sarcoidosis. It also provides an insight into interventions that have been associated with improved HRQoL in sarcoidosis and offers suggestions for future research in this important area. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32583381     DOI: 10.1055/s-0040-1710080

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  2 in total

1.  Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study.

Authors:  Rachel Strykowski; Divya C Patel; Manny Ribeiro Neto; Kerry M Hena; Mridu Gulati; LIsa A Maier; Karen Patterson
Journal:  BMJ Open Respir Res       Date:  2022-07

2.  The Value of a Patient Global Assessment in Management of Sarcoidosis.

Authors:  Robert P Baughman; Jacob Kotzin; Elyse E Lower
Journal:  Lung       Date:  2021-07-13       Impact factor: 2.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.